

CASE REPORT

Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature

Anuja Java,¹ Angelina Edwards,¹ Ana Rossi,¹ Richa Pandey,¹ Joseph Gaut,² Rowena Delos Santos,¹ Brent Miller,¹ Christina Klein¹ and Daniel Brennan¹

¹ Department of Transplant Nephrology, Washington University School of Medicine, St. Louis, MO, USA

² Department of Pathology, Washington University School of Medicine, St. Louis, MO, USA

Keywords

atypical hemolytic uremic syndrome, cytomegalovirus, eculizumab, renal transplant thrombotic microangiopathy.

Correspondence

Anuja Java MD, Department of Nephrology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8045, St. Louis, MO 63110, USA.

Tel.: 314 362 8391;

fax: 314 362 1366;

e-mail: ajava@dom.wustl.edu

Conflicts of interest

Daniel Brennan has research support from Bristol-Myers Squibb and Alexion and is on the speakers bureau for Alexion. Christina Klein is on the speakers bureau for Alexion.

Received: 5 February 2015

Revision requested: 9 March 2015

Accepted: 7 April 2015

Published online: 24 April 2015

doi:10.1111/tri.12582

Introduction

Thrombotic microangiopathy is a disease of the microvasculature characterized by arteriolar thickening, endothelial swelling, intraluminal platelet thrombi, and red blood cell (RBC) fragmentation as blood flows across the partially occluded microcirculation. Consumption of platelets and RBCs causes thrombocytopenia, microangiopathic hemolytic anemia, and varying degrees of tissue ischemia and organ dysfunction. It is a well-recognized complication of bone marrow, liver, heart transplant and can be particularly devastating after a kidney transplant. It may occur *de novo*

Summary

De novo thrombotic microangiopathy (TMA) after renal transplant is rare. Cytomegalovirus (CMV)-related post-transplant TMA has only been reported in 6 cases. We report an unusual case of a 75-year-old woman who developed *de novo* TMA in association with CMV viremia. The recurrence of TMA with CMV viremia, the resolution with treatment for CMV, and the lack of correlation with a calcineurin inhibitor (CNI) in our case support CMV as the cause of the TMA. What is unique is that the use of eculizumab without plasmapheresis led to prompt improvement in renal function. After a failure to identify a genetic cause for TMA and the clear association with CMV, eculizumab was discontinued. This case provides insight into the pathogenesis and novel treatment of *de novo* TMA, highlights the beneficial effects of complement inhibitors in this disease, and shows that they can be safely discontinued once the inciting etiology is addressed.

or recur in the allograft. Two clinical entities have been described: thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS).

Hemolytic uremic syndrome is a TMA featuring a triad of hemolytic anemia, thrombocytopenia, and acute renal failure (ARF). Atypical HUS (aHUS) is distinguished by the absence of Shiga toxin producing *E. coli* infection and results from complement-mediated damage to the microvascular endothelium. Mutations in genes encoding proteins of the alternative pathway account for 50–70% of cases. The heterozygous mutations in aHUS are mostly rare or unique and deleterious [1].

Cytomegalovirus is a ubiquitous herpesvirus transmitted through multiple ways, including solid-organ transplantation. In an immunocompromised host, the virus causes disease by primary infection or after reactivation. CMV is a risk factor for decreased renal allograft survival due to a multitude of effects such as acute and chronic rejection, atherosclerosis, transplant renal artery stenosis [2], and opportunistic infections.

We report an unusual case of *de novo* post-transplant TMA/aHUS in association with CMV viremia successfully treated with eculizumab.

Case report

A 75-year-old Caucasian woman with ESRD from diabetes underwent a 4-antigen mismatched, CMV donor seronegative into recipient seropositive, deceased donor renal transplant (DDRT) in November 2011. Induction immunosuppression included methylprednisolone 500 mg intra-operatively and rabbit antithymocyte globulin (rATG, Thymoglobulin) 5 mg/kg over 3 days, followed by maintenance azathioprine 150 mg daily (changed from mycophenolic acid due to nausea and vomiting), tacrolimus 2 mg daily (once daily tacrolimus due to slow graft function), and prednisone 5 mg daily. Serum creatinine (SCr) was 1.4 mg/dl at discharge.

In April 2012, the patient developed ARF (SCr = 9.2 mg/dl), requiring hemodialysis (Fig. 1). Allograft biopsy revealed ischemic glomeruli, thrombosis, and interstitial hemorrhage consistent with acute TMA. Systemic evidence of TMA was absent (Hemoglobin = 11 g/dl, Lactate dehydrogenase = 214 U/l, Platelet

count = 137K/cumm, no schistocytes on peripheral smear). The C4d staining and antidonor specific antibodies (DSA) testing were negative ruling out antibody-mediated rejection (AMR). A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS 13) was 75% and Shiga toxin *E. coli* was negative. Thus, a diagnosis of aHUS was made. A single dose of Eculizumab (1200 mg) was given with prompt improvement in urine output and SCr (Fig. 1). Infectious workup demonstrated CMV viremia (2582 copies/ml), *Citrobacter* bacteremia, and *Enterococcus* pyelonephritis, which was treated with valganciclovir (VGCV; renally dosed at 450 mg every 48 h), meropenem, and vancomycin. An echocardiogram was negative for endocarditis. Belatacept was substituted for tacrolimus for possible CNI-induced TMA. Once CMV viremia cleared by 21 days, the VGCV dose was reduced to prophylactic levels (450 mg po daily) for 3 months and then discontinued. Creatinine stabilized at 1.8 mg/dl.

One month after VGCV discontinuation, she became oliguric and SCr abruptly rose to 6.6 mg/dl. Allograft biopsy showed recurrent TMA, which was again renal confined. The C4d staining and DSA were negative. A whole blood CMV-PCR was positive but unable to quantify because of its low value (<2000 copies/ml). The VGCV was resumed at therapeutic doses (450 mg po every 48 h). Belatacept was discontinued and eculizumab 1200 mg administered. Within 12 h, urine output increased to over 2 l/day and the creatinine improved to 2.0 mg/dl over 3 weeks. The CMV viremia resolved within 2 weeks. Eculizumab was continued for another 3 months until 1-year anniversary of her transplant and then discontinued. Valganciclovir was




Figure 1 Acute renal failure secondary to thrombotic microangiopathy after CMV viremia, at 5 months and 9 months post-transplant, successfully treated with valganciclovir and eculizumab.

continued at prophylactic doses (450 mg po daily). Analysis of blood for the TMA panel showed normal alleles for factor B, factor H, factor I, membrane cofactor protein (MCP; CD46), C3, FHR1-FHR3 genes, and thrombomodulin. Repeat biopsy 2 months later showed chronic TMA features.

Three years after transplant and more than 2 years after initial treatment, the patient has remained clinically stable with a serum creatinine of 1.8 mg/dl with negligible proteinuria (100 mg/day). Her immunosuppressive regimen consists of azathioprine, 100 mg po daily and prednisone, 5 mg po daily. We plan to continue prophylactic doses of VGCV (450 mg po daily) indefinitely to prevent CMV recurrence.

Discussion

The incidence of *de novo* TMA is 0.8–15% with graft loss occurring in over one-third of cases [3]. It localizes to the graft in about 30% cases [4]. The time from transplant to diagnosis of TMA ranges from a few days to years after transplantation. Risk factors include use of immunosuppressive drugs [5], viral infections [6–8], ADAMTS 13 inhibitors, and malignancy [9]. The lesion may be associated with AMR where a kidney biopsy helps distinguish the two. In addition, evidence suggests a genetic susceptibility to *de novo* TMA in patients with complement gene abnormalities, similar to aHUS [10,11].

Although the pathogenesis is incompletely understood, investigators speculate that an initial insult by ischemia–reperfusion may be undesirably enhanced by viral infections, immunosuppressive drugs, or dysregulated complement activation [12].

CMV as a trigger for post-transplant TMA has only been reported in six cases (Reviewed in Table 1). Evidence suggests that CMV can directly damage endothelial cells and cause platelet adhesion by inducing the expression of adhesion molecules and release of von Willebrand factor [13]. This pathogenic sequence of events where endothelial damage can lead to microvascular thrombosis can help establish why CMV and TMA may be closely related. However, it has been shown that quantitative CMV-PCR may not correlate with renal allograft pathology or with the detection of CMV inclusions in renal tissue [14,15].

The recurrence of TMA with CMV viremia, the resolution of the acute TMA with treatment for CMV, and the lack of correlation with a CNI in our case support CMV as the cause of the TMA. What is unique is that the use of eculizumab without plasmapheresis led to prompt improvement in renal function.

Eculizumab is a humanized monoclonal antibody against C5, which inhibits the cleavage of C5 into C5a and C5b, thus preventing the formation of the membrane attack complex (MAC). CMV has been reported to cause direct activation of the classical pathway mediated by binding of C1q to CMV-infected cells, resulting in MAC formation and ultimately cellular lysis and death. The virus itself, however, evades the complement system by incorporating complement regulatory proteins (CD55 and CD59) into its virion [16].

We believe that prompt administration of eculizumab prevented complement-mediated destruction of host cells by the virus, thus creating a window of opportunity for the clearance of viremia by VGCV. This is consistent with our observation that improvement in urine output and renal function preceded the clearance of viremia.

Table 1. Review of literature.

Cases	Presentation	Treatment	Outcome
Hochstetler et al. [20]	a) <i>De novo</i> TMA 2 months post-kidney–pancreas transplant; new IgM anti-CMV Ab detected b) Series of 22 patients with <i>de novo</i> TMA after DDRT; 42% developed active CMV infection	IV immunoglobulin	Complete recovery
Jeejeebhoy & Zaltzman [21]	<i>De novo</i> TMA associated with primary CMV disease 6 weeks post-transplant	Condition worsened with daily PE but responded to IV Ganciclovir	Complete recovery
Waiser et al. [6]	<i>De novo</i> HUS 5 days after patient developed biopsy proven CMV esophagitis	IV Ganciclovir	Complete recovery
Waiser et al. [6]	<i>De novo</i> HUS within 3 days after onset of primary CMV disease	IV Ganciclovir	Complete recovery
Olie et al. [22]	TMA post-transplant in a patient with familial HUS with factor H mutation 10 months post-transplant successfully treated. Recurrent TMA with CMV relapse	IV Ganciclovir; PE	Complete recovery
De Keyzer et al. [23]	<i>De novo</i> TMA 25 years post-transplant in association with CMV esophagitis, gastritis and pneumonitis	Daily PE, IV Ganciclovir, CMV Ig and IV foscarnet	Allograft loss; 2nd transplant

The numbers in parenthesis refer to the number in the references.

After a failure to identify a genetic cause for aHUS and in the absence of CMV recurrence, eculizumab was discontinued.

Eculizumab is FDA-approved for the treatment of paroxysmal nocturnal hemoglobinuria, and since 2009, it has been recognized as a life-saving option for patients with aHUS [17]. Although well tolerated and relatively safe, the optimal therapeutic regimen for this drug still remains unclear as much as the necessity for life-long administration and as such warrants large scale prospective randomized trials. Because we did not identify a complement genetic abnormality, and due to the convincing role of CMV in the pathogenesis, we believed we could safely discontinue eculizumab but continue to control CMV through the use of indefinite valganciclovir which is expensive, approximately \$10 000 per year but much less than the cost of eculizumab at approximately \$500 000 per year. However, a genetic mutation as the cause for the aHUS is only found in 50% of cases [18]. Interestingly, a recent report of 10 patients with aHUS with an identified complement abnormality showed that eculizumab could be discontinued in 7 of 10 patients [19].

Authorship

AJ, AE, AR, RP, JG, RDS, BM, CK and DB: Conception or design, or analysis and interpretation of data, or both; drafting the article or revising it; providing intellectual content of critical importance to the work described; final approval of the version to be published.

Funding

This research was supported by NIH 5T32 DK007126 (AJ) and in part by the Alan A. and Edith L. Wolff endowment, the Eileen M. Brooks Fund, and Donald F. Roach to Daniel C. Brennan.

Ethics

The patient authorized Washington University to disclose to media representatives and/or public affairs staff members protected health information and information about herself, her condition or treatment for the purposes of publicity, promotion, education or publication in print, broadcast, and electronic media. A signed consent form is on file at Washington University School of Medicine.

References

1. Java A, Atkinson J, Salmon J. Defective complement inhibitory function predisposes to renal disease. *Annu Rev Med* 2013; **64**: 307.

2. Audard V, Matignon M, Hemery F, et al. Risk factors and long-term outcome of transplant renal artery stenosis in adult recipients after treatment by percutaneous transluminal angioplasty. *Am J Transplant* 2006; **6**: 95.
3. Reynolds JC, Agodoa LY, Yuan CM, Abbott KC. Thrombotic microangiopathy after renal transplantation in the United States. *Am J Kidney Dis* 2003; **42**: 1058.
4. Schwimmer J, Nadasdy TA, Spitalnik PF, Kaplan KL, Zand MS. *De novo* thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. *Am J Kidney Dis* 2003; **41**: 471.
5. Zarifian A, Meleg-Smith S, O'Donovan R, Tesi RJ, Batuman V. Cyclosporine-associated thrombotic microangiopathy in renal allografts. *Kidney Int* 1999; **55**: 2457.
6. Waiser J, Budde K, Rudolph B, Ortner MA, Neumayer HH. *De novo* hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. *Am J Kidney Dis* 1999; **34**: 556.
7. Murer L, Zacchello G, Bianchi D, et al. Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. *J Am Soc Nephrol* 2000; **11**: 1132.
8. Petrogiannis-Haliotis T, Sakoulas G, Kirby J, et al. BK-related polyomavirus vasculopathy in a renal-transplant recipient. *N Engl J Med* 2001; **345**: 1250.
9. Gohh RY, Williams ME, Crosson AW, Federman M, Zambetti FX. Late renal allograft failure secondary to thrombotic microangiopathy associated with disseminated malignancy. *Am J Nephrol* 1997; **17**: 176.
10. Kavanagh D, Richards A, Atkinson JP. Complement regulatory genes and hemolytic uremic syndromes. *Annu Rev Med* 2008; **59**: 293.
11. Abarrategui-Garrido C, Melgosa M, Pena-Carrion A, et al. Mutations in proteins of the alternative pathway of complement and the pathogenesis of atypical hemolytic uremic syndrome. *Am J Kidney Dis* 2008; **52**: 171.
12. Ponticelli C, Banfi G. Thrombotic microangiopathy after kidney transplantation. *Transpl Int* 2006; **19**: 789.
13. Rahbar A, Soderberg-Naucler C. Human cytomegalovirus infection of endothelial cells triggers platelet adhesion and aggregation. *J Virol* 2005; **79**: 2211.
14. Liapis H, Storch GA, Hill DA, Rueda J, Brennan DC. CMV infection of the renal allograft is much more common than the pathology indicates: a retrospective analysis of qualitative and quantitative buffy coat CMV-PCR, renal biopsy pathology and tissue CMV-PCR. *Nephrol Dial Transplant* 2003; **18**: 397.
15. Grim SA, Pereira E, Guzman G, Clark NM. CMV PCR as a diagnostic tool for CMV gastrointestinal disease after solid organ transplantation. *Transplantation* 2010; **90**: 799.
16. Loenen WA, Bruggeman CA, Wiertz EJ. Immune evasion by human cytomegalovirus: lessons in immunology and cell biology. *Semin Immunol* 2001; **13**: 41.
17. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic

- syndrome and C3 glomerulopathies. *Nat Rev Nephrol* 2012; **8**: 643.
18. Noris M, Caprioli J, Bresin E, *et al.* Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. *Clin J Am Soc Nephrol* 2010; **5**: 1844.
 19. Ardissino G, Testa S, Possenti I, *et al.* Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. *Am J Kidney Dis* 2014; **64**: 633.
 20. Hochstetler LA, Flanigan MJ, Lager DJ. Transplant-associated thrombotic microangiopathy: the role of IgG administration as initial therapy. *Am J Kidney Dis* 1994; **23**: 444.
 21. Jeejeebhoy FM, Zaltzman JS. Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient: a new treatment strategy. *Transplantation* 1998; **65**: 1645.
 22. Olie KH, Goodship TH, Verlaak R, *et al.* Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir. *Am J Kidney Dis* 2005; **45**: e12.
 23. De Keyzer K, Van Laecke S, Peeters P, Vanholder R. *De novo* thrombotic microangiopathy induced by cytomegalovirus infection leading to renal allograft loss. *Am J Nephrol* 2010; **32**: 491.